综合性有氧运动和多感官环境训练,通过海马前额神经回路调制来治疗与年龄相关的认知衰退
Huawei Lin1,2, Yuxi Qiu1,3, Zhongyi Hu1,3
1Institute of Rehabilitation Industry, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, Fujian Province, China.
Molecular neurobiology
|November 28, 2025
概括
联合训练 (有氧运动和多感官刺激) 有效地减轻小鼠与年龄相关的认知衰退. 这种干预增强了海马和前额叶皮层的活动,突出了神经回路在认知改善中的重要性.
科学领域:
- 神经科学是一个神经科学.
- 衰老研究研究 衰老研究
- 认知科学 认知科学
背景情况:
- 与年龄相关的认知衰退对老年人的健康构成重大挑战.
- 现有的干预措施,如有氧运动和环境丰富,显示出希望,但缺乏明确的机制理解.
- 老龄化过程中认知能力改善的神经基础在很大程度上仍未被探索.
研究的目的:
- 研究一种新的综合训练 (CT) 干预措施,包括有氧运动 (AE) 和多感官刺激环境训练 (MSET),对老年小鼠认知能力下降的疗效.
- 阐明神经机制,特别是海马-前额叶皮层 (HPC-PFC) 电路的作用,这是CT的认知益处的基础.
- 在HPC和PFC中识别CT调制的分子标.
主要方法:
- 在老年小鼠中开发和应用综合训练 (CT) 方案.
- 在CT,AE,MSET或对照条件下评估认知功能.
- 神经电路跟踪和化学遗传学探讨HPC-PFC电路的作用.
- 单细胞测序以确定HPC和PFC中的分子变化.
主要成果:
- 在老年小鼠中,CT显著减轻了认知衰退,优于单个AE或MSET.
- CT增加了海马体 (HPC) 和前额皮层 (PFC) 中的神经元活动和突触可塑性.
- HPC-PFC电路操纵证明了其在CT介导认知增强中的关键作用.
- CT调节了特定的分子标:AE通过PCSK1N和LY6H,MSET通过DPP6和GRINA,CT对这些分子进行上调.
结论:
- 综合训练 (CT) 为缓解与年龄相关的认知衰退提供了一种有效的策略.
- HPC-PFC神经电路对于CT观察到的认知益处至关重要.
- 在HPC和PFC中CT诱导的分子变化有助于认知改善,提供潜在的治疗点.
更多相关视频
07:01Working Memory Training for Older Participants: A Control Group Training Regimen and Initial Intellectual Functioning Assessment
Published on: September 20, 2020
5.1K
07:27Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
10.6K
相关概念视频
Cognitive Development During Adulthood
737
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
737
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
